Edition:
India

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

44.40SEK
18 Feb 2019
Change (% chg)

1.50kr (+3.50%)
Prev Close
42.90kr
Open
43.00kr
Day's High
44.95kr
Day's Low
42.85kr
Volume
591,865
Avg. Vol
1,354,522
52-wk High
44.95kr
52-wk Low
25.25kr

Latest Key Developments (Source: Significant Developments)

Karo Pharma Q4 EBITDA Rises To SEK 165.4 Million
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Karo Pharma AB ::Q4 EBITDA SEK 165.4 MILLION VERSUS SEK 41.8 MILLION YEAR AGO.Q4 NET SALES SEK 463.3 MILLION VERSUS SEK 238.7 MILLION YEAR AGO.  Full Article

Karo Intressenter AB Owns About 66.5 Pct Of Outstanding Shares In Karo Pharma AB
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - EQT AB::AFTER EXPIRY OF FINAL ACCEPTANCE PERIOD.KARO INTRESSENTER AB OWNS ABOUT 66.5 PCT OF OUTSTANDING SHARES IN KARO PHARMA AB AFTER EXPIRY OF FINAL ACCEPTANCE PERIOD.  Full Article

EQT makes 6 bln SEK bid for specialty pharma firm Karo Pharma
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Karo Pharma AB ::EQT VIII, THROUGH KARO INTRESSENTER AB, ANNOUNCES A PUBLIC CASH OFFER TO THE SHAREHOLDERS IN KARO PHARMA AKTIEBOLAG.EQT SAYS PUBLIC CASH OFFER TO SHAREHOLDERS IN KARO PHARMA AKTIEBOLAG TO ACQUIRE SHARES IN KARO PHARMA AT A PRICE OF SEK 36.90 PER SHARE.EQT SAYS TOTAL OFFER VALUE BASED ON ALL OUTSTANDING SHARESIN KARO PHARMA AMOUNTS TO SEK 5,973 MILLION.EQT SAYS OFFER IS FULLY FINANCED THROUGH EQUITY FROM EQT VIII.EQT SAYS OFFER REPRESENTS A PREMIUM OF 25.3 PER CENT FOR SHARES IN RELATION TO CLOSING PRICE FOR SHARES ON NASDAQ STOCKHOLM ON 26 OCTOBER 2018.EQT SAYS BOARD OF DIRECTORS OF KARO PHARMA HAS UNANIMOUSLY RECOMMENDED THAT COMPANY'S SHAREHOLDERS ACCEPT OFFER.EQTSAYS ANDERS LONNER, CHAIRMAN OF COMPANY'S BOARD OF DIRECTORS, AND PER-ANDERS JOHANSSON, MEMBER OF COMPANY'S BOARD OF DIRECTORS, TOGETHER REPRESENTING IN ABT 13.6 PERCENT OF OUTSTANDING VOTES IN COMPANY, HAVE DECLARED THAT THEY INTEND TO ACCEPT OFFER.  Full Article

Karo Pharma Triples Sales And Profit In The Second Quarter
Thursday, 19 Jul 2018 

Karo Pharma AB ::KARO PHARMA TRIPLES SALES AND PROFIT IN THE SECOND QUARTER.EBITDA Q2 AMOUNTED TO MSEK 232.3 (49.7).Q2 NET SALES MSEK 489.4 (142.5).QUARTER WAS POSITIVELY IMPACTED BY FACT THAT AC-QUIRED PRODUCTS FROM LEO WERE INCLUDED FOR FIRST TIME..KARO PHARMA - "EXPECTED FUTURE PROFITS IMPLIES THAT WE CAN NOW UTILIZE OUR TAX LOSSES FOR A NUMBER OF YEARS TO COME, WHICH WILL HAVE A MAJOR POSITIVE IMPACT ON OUR CASH FLOW".  Full Article

Karo Pharma To Acquire Own Shares
Wednesday, 9 May 2018 

May 9 (Reuters) - KARO PHARMA AB ::HAS DECIDED TO ACQUIRE OWN SHARES.A MAXIMUM OF 10,000,000 SHARES SHALL BE ACQUIRED.  Full Article

Karo Pharma Determines Terms For Rights Issue
Monday, 30 Apr 2018 

April 30 (Reuters) - Karo Pharma AB ::THE TERMS FOR KARO PHARMA'S RIGHTS ISSUE HAVE BEEN DETERMINED.FOR EACH EXISTING SHARE HELD AT RECORD DATE, SHAREHOLDERS WILL RECEIVE ONE (1) SUBSCRIPTION RIGHT.SUBSCRIPTION PRICE HAS BEEN SET AT SEK 24.00 PER SHARE.RIGHTS ISSUE WILL AT MOST RAISE SEK 1,314.7 MILLION BEFORE ISSUE COSTS.ISSUANCE OF A MAXIMUM OF 54,777,594 NEW ORDINARY SHARES.TWO (2) SUBSCRIPTION RIGHTS ENTITLING HOLDER TO SUBSCRIBE FOR ONE (1) ORDINARY NEW SHARE (I.E. A SUBSCRIPTION RATIO OF 1:2).SUBSCRIPTION PERIOD WILL RUN BETWEEN 14 MAY 2018 UNTIL 29 MAY 2018.  Full Article

Karo Pharma: Board Of Directors Resolves On Fully Guaranteed Rights Issue
Wednesday, 4 Apr 2018 

April 4 (Reuters) - KARO PHARMA AB ::THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING.IS EXPECTED TO RECEIVE ISSUE PROCEEDS AMOUNTING TO ABOUT SEK 1.3 BILLION BEFORE TRANSACTION COSTS.  Full Article

Karo Pharma Rights Issue Subscribed To 170 Percent
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - KARO PHARMA AB ::RIGHTS ISSUE SUBSCRIBED TO 170 PERCENT WITH PROCEEDS AT ABOUT SEK 794.3 MILLION BEFORE ISSUE COSTS.  Full Article

Karo Pharma: New Issue To Provide Up To SEK 794.3 Ml‍n Before Issue Costs
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Karo Pharma Ab ::SAYS NEW ISSUE TO PROVIDE UP TO SEK 794.3 ML‍N BEFORE ISSUE COSTS.  Full Article

Karo Pharma Chairman Called For Inquiry For Inside Trading
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Karo Pharma Ab ::CHAIRMAN CALLED IN TO INQUIRY FROM POLICE FOR INSIDE TRADING.BOARD CONCLUDES THE THAT CHAIRMAN HAS ACTED CORRECTLY AND DID NOTHING WRONG, AS PER ITS INVESTIGATION.  Full Article

Private equity firm EQT increases offer for Sweden's Karo Pharma

STOCKHOLM, Jan 2 Private equity firm EQT on Wednesday bumped up its offer for Swedish specialty pharma group Karo Pharma to 6.15 billion Swedish crowns ($694 million), citing in part stock market performance since its original offer two months ago.